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Comparative effectiveness research (CER) is intended to address the
expressed needs of patients, clinicians, and other stakeholders.
Representatives of 54 stakeholder groupswith an interest in chronic
obstructive pulmonary disease (COPD) participated in workshops
convened by the COPD Outcomes-based Network for Clinical Effec-
tiveness and Research Translation (CONCERT) over a 2-year period.
Year 1 focusedon chronic care and care coordination. Year 2 focused
on acute care and transitions in care between healthcare settings.
Discussions and provisional voting were conducted via teleconfer-
ences and e-mail exchanges before the workshop. Final prioriti-
zation votes occurred after in-person discussions at the workshop.
We used a modified Delphi approach to facilitate discussions and
consensus building. To more easily quantify preferences and to
evaluate the internal consistency of rankings, the Analytic Hierarchy
Processwas incorporated in Year 2. Results of preworkshop andfinal
workshop voting often differed, suggesting that prioritization ef-
forts relying solely on requests for topics from stakeholder groups
without in-person discussion may provide different research prior-
ities. Research priorities varied across stakeholder groups, but ge-
nerally focused on studies to evaluate different approaches to
healthcare delivery (e.g., spirometry for diagnosis and treatment,
integrated healthcare strategies during transitions in care) rather
than head-to-head comparisons ofmedications. This research agen-
da may help to inform groups intending to respond to CER funding
opportunities in COPD. The methodologies used, detailed in the
online supplement, may also help to inform prioritization efforts for
CER in other health conditions.
Keywords: health services research; research priorities; care coordina-
tion; stakeholders
Limited information exists regarding the comparative harms and
benefits of treatment alternatives to guide healthcare decision
making by patients, clinicians, and other stakeholders in usual
practice settings (1). Also, healthcare costs have continued to
increase as new and often more expensive treatments are adop-
ted into practice, often without adequate evidence to support
their use over existing alternatives (2). These considerations have
sparked interest in comparative effectiveness research (CER),
which consists of head-to-head comparisons of interventions, in-
cluding pharmacologic agents, devices, and strategies for delivering
healthcare (3). Several federally-funded programs have accelerated
CER in the United States, including the Effective Health Care
Program (2003), the American Recovery and Reinvestment Act
(2009), and, most recently, provisions in the Affordable Care Act
(2010), which authorized the creation of the Patient-Centered Out-
comes Research Institute (4, 5). Funding opportunity announce-
ments for CER, including those by Patient-Centered Outcomes
Research Institute, have emphasized the importance of conducting
studies that directly address the needs of patients, clinicians, and
other stakeholders who use health-related information to ensure
that the most important gaps in evidence for decision making are
addressed. The Division of Lung Diseases of the National Heart,
Lung, and Blood Institute convened a workshop on CER and also
recommended engaging a diverse group of stakeholders to iden-
tify and prioritize questions for CER (6).
Chronic obstructive pulmonary disease (COPD) is a lung con-
dition characterized by airflow limitation, progressive dyspnea,
and cough, and is punctuated by episodic deteriorations (exac-
erbations). COPD is a leading cause of morbidity and mortality
worldwide (7, 8) and the third leading cause of death in the
United States (9, 10). A majority of patients with COPD have
at least one other chronic condition (e.g., hypertension, heart
failure, depression), receive care from more than one healthcare
provider (e.g., primary care and specialist physicians, nurses, res-
piratory therapists), and cycle between chronic and acute care
settings (e.g., outpatient clinic, hospital). Thus, CER topics for
COPD need to address different aspects of COPD healthcare,
including chronic care, care coordination, acute care, and tran-
sitions in care between healthcare settings.
Representatives of diverse stakeholder groups with an inter-
est in COPD participated in premeeting teleconferences and
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in-person workshops convened by the COPD Outcomes-based
Network for Clinical Effectiveness and Research Translation
(CONCERT) over a 2-year period (11). Stakeholders included
patient advocacy groups, private health plans/payers, physician
and nonphysician professional organizations, quality improvement
organizations, industry, research organizations, and government
agencies that fund research (Table 1). Participants were not
asked to disclose potential conflicts of interest (clinical, intellec-
tual, or financial), but their biographies and roles in the stake-
holder organization they were representing were included in
meeting materials provided to all participants. Stakeholders were
asked to develop a CER agenda for COPD in each of the follow-
ing four areas: (1) chronic care, (2) care coordination, (3) acute
care, and (4) transitions in care between healthcare settings. The
workshop in Year 1 consisted of research prioritization activities
for chronic care and care coordination, whereas the workshop in
Year 2 focused on acute care and transitions in care for patients
with COPD.
In this workshop report, we discuss the methodology and de-
velopment of a national CER agenda for COPD, which may help
to inform groups intending to respond to funding opportunities
for CER in COPD. A detailed description of the methodology,
including topic selection, voting procedures, and discussion
about the strengths and limitations of the methodology, are
available in the online supplement. In brief, stakeholders partic-
ipated in preworkshop discussions to plan the meeting and to de-
velop a provisional list of research priorities. Stakeholders then
voted to identify provisional CER priorities before the in-person
workshop, and the provisional topics were included in meeting
material provided to participants (see Tables E2 and E3 in the
online supplement). At the Year 1 and 2 workshops, we used
the modified Delphi approach (12, 13), a standard approach to
consensus development. At the conclusion of the Year 1 work-
shop, attendees completed a 10-question online satisfaction sur-
vey to provide anonymous feedback regarding the format and
content of the meeting and to inform the planning for the second
workshop. At the Year 2 workshop, we used the analytic hierar-
chy process (AHP; 14–16) to more easily quantify relative pref-
erences for the various CER topics and to assess the internal
consistency of voting. At the conclusion of the Year 2 workshop,
stakeholders were asked to vote on the importance of various
criteria used to set CER priorities. Before finalizing this work-
shop report, stakeholders and members of an External Advisory
Committee (see ACKNOWLEDGMENTS) were invited to submit
comments to a draft containing the prioritized research agenda.
STAKEHOLDER PARTICIPATION
Fifty-four stakeholder groups participated in the workshops (82%
of 66 invited groups; Table 1), including 3 patient advocacy
groups (4 invited), 4 health plans (5 invited), 18 professional
organizations representing clinicians (24 invited), 3 quality
improvement/accreditation organizations (4 invited), 1 repre-
sentative of industry (2 invited), 11 research organizations (12 in-
vited), 9 speakers (9 invited), and 5 government agencies (6
invited). Of the total 54 stakeholder groups invited for Year 1
and 2 workshops, 33 groups participated in Year 1 (38 individuals)
and 42 groups participated in Year 2 (51 individuals). We did not
collect information about why stakeholder groups participated in
one but not both workshops. In cases in which there was more
than one representative from a single stakeholder group, only one
voting representative was permitted. The draft research questions
and rationale proposed by stakeholders for each CER topic are
provided in Tables E1 to E3. We present below the priorities for
CER topics in each of the four areas (chronic care, care coordi-
nation, acute care, and transitions in care).
PRIORITIES FOR COMPARATIVE EFFECTIVENESS
RESEARCH IN COPD
Chronic Care
Nine topics for chronic care were identified (Table 2). Prework-
shop voting results indicated that all topics were important, with
little separation (median importance scores 2–4; possible range
1–9). After discussions at the workshop, stakeholders were asked
to rank the importance of topics to more easily distinguish between
preferences. Final voting results indicated that Spirometry for di-
agnosis and treatment was the highest-priority topic (median rank
1). However, there remained substantial overlap in priorities. For
example, three topics (Effectiveness of pulmonary rehabilitation,
Effectiveness of COPD care and guideline care translation, and
Home care) all had a median rank of 4, the second-highest priority
rank. The interquartile ranges (IQRs) for ranks were also relatively
wide, suggesting variable preferences among stakeholder groups.
Care Coordination
Eleven care coordination topics were identified (Table 3). As with
chronic care topics, preworkshop voting results rated all care co-
ordination topics as important. Final voting, using ranks, identified
Management of COPD in the presence of comorbidity and Pul-
monary rehabilitation as a model for care coordination as the high-
est two priorities (median ranks 3 and 3.5, respectively). However,
none of the care coordination topics achieved a median rank of 1,
and the IQRs for ranks were wide, indicating again substantial
variability in preferences across stakeholder groups.
Acute Care
Eight topics for acute care (Table 4) were identified. Despite use
of ranks for preworkshop voting, several topics had similar lev-
els of importance (e.g., five topics had median ranks of 3–4 for
acute COPD care).
Final voting results, using AHP to rank topics, indicated that
Implementation of COPD exacerbation checklist, Comorbid con-
ditions in the acute setting, and Effectiveness and implementation of
noninvasive ventilation (NIV) were the most highly voted topics.
These three topics had very similar idealized priority scores (1.0
[reference], 0.95, 0.80, respectively), indicating that Comorbid
conditions andNIV topics were voted as at least 80% as important
as Implementation of COPD exacerbation checklist. By contrast,
the two lowest ranked topics (Oxygen therapy postexacerbation
and Interventions for acute airway obstruction) were viewed as
one-fifth as important (idealized priority scores about 0.2).
Transitions in Care
Seven topics for transitions in care were identified (Table 5). Final
voting results, again using AHP, indicated that the highest priority
topic, Integrated healthcare strategies during transitions in COPD
care (e.g., early hospital discharge to pulmonary rehabilitation)
was rated as more than twice as important as the second-highest
preferences (Multimorbidity and Patient and family activation).
The consistency ratio (CR) for voting patterns for acute care
topics and for transition in care topics was less than 0.1 for each, sug-
gesting that expressed preferences by stakeholders were overall in-
ternally consistent. See online supplement for further explanation.
SATISFACTION WITH WORKSHOPS
Feedback indicated high levels of satisfaction among workshop
participants (Table 6). Overall, Year 1 workshop attendees sup-
ported the need for a 2-day meeting, with presentations on the
first day framing the subsequent day’s discussion and voting. A
similar format was therefore used in Year 2.
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TABLE 1. STAKEHOLDER GROUPS PARTICIPATING IN CHRONIC OBSTRUCTIVE PULMONARY




Alpha 1 Foundation Robert Sandhaus, M.D., Ph.D.*
Respiratory Health Association of Metropolitan Chicago Stacy Ignoffo, M.S.W.*†
COPD Foundation Margaret Brown, M.S.†‡
John Walsh*†
Health plans
Blue Cross/Blue Shield Mike Belman, M.D., M.P.H.*
Mark Mattingly, M.D.†
Health Maintenance Organization Research Network Charlene McEvoy, M.D., M.P.H.*†
Douglas Mapel, M.D., M.P.H.*†‡
Kaiser Permanente Richard Mularski, M.D., M.S.H.S., M.C.R.*†
Wellpoint John Whitney, M.D.†
Professional organizations representing clinicians
American Academy of Family Physicians Wilson Pace, M.D.†
American Academy of Sleep Medicine Patrick Strollo, Jr., M.D.*†
American Association of Cardiovascular and Pulmonary Rehabilitation Andrew Ries, M.D., M.P.H.*†
American Association of Respiratory Care Sam Giordano, R.R.T., M.B.A.*†
American Association of Critical Care Nurses Mary Lou Sole, Ph.D., R.N.†
American College of Physicians Joe Ramsdell, M.D.*
American College of Chest Physicians Sandra Adams, M.D., M.S.*†
American College of Emergency Physicians Rita Cydulka, M.D., M.S.*
American Geriatrics Society Carlos Fragoso, M.D.†
American Public Health Association Judi Walden, R.C.P. II, R.R.T.*
Bunny Newman, R.N.*‡
American Thoracic Society David Au, M.D., M.S.*†
Lynn Reinke, Ph.D., A.R.N.P.†‡
Association of Pulmonary and Critical Care Program Directors Brian Carlin, M.D.†
National Association of Social Workers Joan Levy Zlotnik, Ph.D., A.C.S.W.†
Respiratory Nursing Society Donna Bond, D.N.P., R.N.†‡
Anne Boyle, Ph.D., R.N.†
Diane Locke, A.N.P.-B.C., R.N.†‡
Society for Academic Emergency Medicine Eddy Lang, M.D.†‡
Society of General Internal Medicine Chayan Chakraborti, M.D.†
Society of Critical Care Medicine Jonathan Sevransky, M.D., M.H.S.*†
Society of Hospital Medicine Steven Deitelzweig, M.D.†
Greg Maynard, M.D., M.Sc.*
Robert Ryder, M.D.*‡
Quality improvement/accreditation organizations
American Health Quality Association Dale Bratzler, D.O., M.P.H.†
The Joint Commission Lee Ann Baggott, M.D.*
Tim Byrum, M.S.N., N.P.†
National Patient Safety Foundation Manisha Shah, M.D.†
Industry
Boehringer Ingelheim Asif Shaikh, M.D., M.P.H.*‡
Researcher organizations
Baystate Health Peter Lindenauer, M.D., M.S.*†
Canadian Association of Emergency Physicians Research Consortium Brian Rowe, M.D., M.Sc.*
North American Primary Care Research Group Andrew Cave, M.B.*†
Ohio State University Gerene Bauldoff, Ph.D., R.N.*
Olmstead Medical Center Barbara Yawn, M.D., M.Sc.*†
Pittsburgh Regional Health Initiative Keith Kanel, M.D.†‡
Society for Medical Decision Making Kathryn McDonald, M.M.†
The Center for Health Research, Kaiser Permanente Mary Ann McBurnie, Ph.D.*†
William Vollmer, Ph.D.*†‡
University of Chicago Jerry A. Krishnan, M.D., Ph.D.*†
Edward T. Naureckas, M.D.†‡
University of Illinois Todd Lee, Pharm.D., Ph.D.*†
University of North Carolina Shannon S. Carson, M.D.*†
Speakers
Johns Hopkins University Cynthia Boyd, M.D., M.P.H.*‡
Robert Wise, M.D.†‡
Harvard University Bartolome Celli, M.D.*‡
National Center for Rural Health Professions Michael Glasser, Ph.D.*‡
The Joint Commission Caroline Isbey, R.N., M.S.N., C.D.E.*‡
RTI International Kenneth LaBresh, M.D.†‡
Denver Health Medical Center Fred Masoudi, M.D., M.S.P.H.*‡
University of Alberta Brian Rowe, M.D., M.Sc.†‡
Northwestern University Mark Williams, M.D.†‡
(Continued )
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CRITERIA USED BY STAKEHOLDERS FOR PRIORITIZING
CER TOPICS
Stakeholders were asked to rank the importance of seven criteria
when making decisions about priorities for CER (Table 7).
Twenty-three (55% of 42 groups participating in Year 2) com-
pleted ballots describing the criteria used to set CER priorities,
so results should be viewed cautiously. The Impact on patient-
centered health outcomes was voted as most important, followed by
Quality of the evidence, Societal costs of care, and Variability in care.
LESSONS LEARNED AND RECOMMENDATIONS
FOR CER IN COPD
Four primary findings emerged from theworkshops to elicit national
priorities for CER in COPD: (1) engaging diverse stakeholders is
feasible and can be used to identify support for CER topics; (2)
efforts to develop and prioritize a research agenda based solely on
requests for topics from stakeholder groups without discussion may
provide different priorities for CER compared with efforts that
incorporate discussion; (3) preferences for CER and criteria used
to select CER topics varied across stakeholder groups; however,
stakeholder support was strongest for studies to evaluate and to
improve healthcare delivery in usual practice settings; and (4) the
AHP helped to quantify the relative preferences for CER and to
evaluate the internal consistency of stakeholder voting patterns.
A diverse group of 54 stakeholders representing patients,
clinicians, and other healthcare decision makers participated
in the development of the national research agenda for CER in
COPD. Survey results indicated high levels of support for the ap-
proach used byCONCERT, including preworkshop discussions to
plan the meeting and elicit a provisional list of research priorities,
followed by in-person workshops with presentations and discus-
sion before final voting. We suspect that stakeholders benefited
from a structured approach for information sharing and to work
with those with differing perspectives. A limitation of the meth-
odology used in setting research priorities is the potential for
conflicts of interests (e.g., clinical, intellectual, or financial) to in-
fluence voting patterns of individual participants. We were not
aware of standards regarding the disclosure and management




Agency of Healthcare Research and Quality Anne Elixhauser, Ph.D.†‡
Supriya Janakiraman, M.D., M.P.H.*†‡
Centers for Medicaid and Medicare Services Mark Levine, M.D.*†‡
National Heart, Lung, and Blood Institute Antonello Punturieri, M.D., Ph.D.†‡
National Institute of Nursing Research Karen Huss, Ph.D., R.N.†‡
National Institute on Aging Basil Eldadah, M.D.†‡
External advisory committee
Oregon Health Sciences University A. Sonia Buist, M.D.*†‡
Johns Hopkins University Cynthia S. Rand, Ph.D.*†‡
VA Puget Sound Health Care System Steve Fihn, M.D., M.P.H.*†‡
University of Calgary Eddy Lang, M.D.*†‡
University of Kentucky David Mannino, M.D.*†‡
Columbia University Peter Wyer, M.D.*†‡
Representatives of 54 stakeholder groups participated in Year 1, Year 2, or both; in some cases, there was more than one
representative from a stakeholder group. Twelve groups were invited but declined or did not respond to the invitation in time to
participate: American Academy of Emergency Medicine, American Heart Association, American Lung Association, American
Medical Association, American Psychiatric Association, Disease Management Association of America, Improvement Science
Research Network, Institute for Health Care Improvement, National Gerontological Nursing Association, PhRMA, United Health
Care, and U.S. Food and Drug Administration. The members of the External Advisory Committee are also listed.
* Participated in Year 1.
y Participated in Year 2.
zNonvoting participant (only one voting representative of each stakeholder group was permitted; speakers, representatives of
industry, members of the External Advisory Committee, and government agencies did not vote on priorities but were invited to
contribute to discussions).
TABLE 2. RESULTS OF YEAR 1 WORKSHOP: CHRONIC CARE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TOPICS
Preworkshop Voting Final Workshop Voting
Importance Scores Importance Ranks
1 (Very Important) to 9 (Most Unimportant) 1 (Most Important) to 9 (Most Unimportant)
Topic Chronic COPD Care Median Score (IQR) Median Rank (IQR)
1 Spirometry for diagnosis and treatment 3 (2–5) 1 (1–4)
2 Effectiveness of pulmonary rehabilitation 3 (1–3) 4 (2–5)
3 Effectiveness of COPD care and guideline translation 2 (1–3) 4 (1–6)
4 Home care 4 (3–5) 4 (3–6)
5 Development of performance measures 3 (1–4) 5 (3–7)
6 Oxygen therapy 2 (1–3) 5 (3–8)
7 Palliation of symptoms 3 (2–4) 7 (5–7)
8 Pharmaceutical treatment 3 (3–4) 7 (6–8)
9 Smoking cessation 2 (1–3) 8 (6–8)
Definition of abbreviations: CER ¼ comparative effectiveness research; COPD ¼ chronic obstructive pulmonary disease; IQR ¼ interquartile range.
There were 33 participating stakeholder organizations in the workshop; individual participants are listed in Table 1. Preferences in the Preworkshop Voting were
expressed as importance scores, whereas importance ranks were used for the Final Workshop voting. Ranks were used in an attempt to more easily separate topics by
level of importance. To more clearly observe differences in priorities within each CER area, stakeholders were informed that no two topics should be assigned the same
importance rank. Wide IQRs suggest variation in stakeholder preferences.
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when we conducted the workshops. There is emerging consensus
on the need for disclosure and management of potential conflicts
of interest when developing clinical practice guidelines; a similar
need exists for groups developing research priorities.
Other groups, including the Institute of Medicine Committee
on Comparative Effectiveness Research Prioritization and the
AHRQCommunity Forum, have engaged stakeholders in devel-
oping CER priorities (but none specifically for COPD) based on
questionnaires, written comments, and oral presentations (1, 17).
By contrast, the methodology used by CONCERT included sus-
tained interactions over a 2-year period.We used a modified Delphi
approach to facilitate discussions and consensus building during the
in-person workshops; it is therefore not surprising that results of
preworkshop votes and final votes at the workshops differed. These
findings suggest that prioritization efforts relying solely on requests
for topics from stakeholder groups without discussion may provide
different priorities for CER compared with efforts that incorporate
discussion. The sustained interest among COPD stakeholders to
participate in prioritization efforts over this 2-year period also raises
the possibility for additional multistakeholder collaborations, in-
cluding the development of specific research proposals (e.g., trans-
lating research topics into specific research questions and study
designs), dissemination of results, and implementation of findings.
In a previous effort to identify CER priorities for COPD over
a shorter (2 mo) period, we asked clinicians and researchers to
nominate potential research topics and then convened a separate
meeting with a limited number of other stakeholder groups (two
health plans, one patient advocacy group, two government agen-
cies, and eight professional societies) for a final overall prioriti-
zation vote (18). We observed substantial variation in stakeholder
preferences, with none achieving an overall rank of 1 (most im-
portant CER topic). In the current effort, we sought to develop
consensus by promoting and sustaining interactions across all
stakeholder groups and by developing a separate list of CER
priorities for different aspects of COPD care (i.e., chronic care,
care coordination, acute care, transitions in care). We also in-
volved a larger number and more diverse group of stakeholders
(e.g., organizations involved in quality improvement or accre-
ditation) and promoted dialogue with experts in effectiveness
and implementation research in the current effort.
Studies to evaluate and to improve healthcare delivery re-
ceived the greatest levels of support, rather than head-to-head
comparisons of specific medications. However, preferences for
CER varied across stakeholder groups even within a specific as-
pect of COPD care (e.g., chronic care), likely because decision
making appears to be governed by a complex matrix of criteria.
TABLE 3. RESULTS OF YEAR 1 WORKSHOP: CARE COORDINATION TOPICS
Preworkshop Voting Final Workshop Voting
Importance Scores Importance Ranks
1 (Very Important) to 9 (Most Unimportant) 1 (Most Important) to 11 (Most Unimportant)
Topic Care Coordination Median Score (IQR) Median Rank (IQR)
1 Management of COPD in the presence of comorbidity 2 (1–3) 3 (2–5)
2 Pulmonary rehabilitation as model for care coordination 3 (1–3) 3.5 (2–8)
3 Impact of depression and mental health management 3 (1–3) 5 (4–8)
4 Measurement of quality of care coordination 3 (2–4) 6 (2–7)
5 Quality of care coordination 3 (2–3) 6 (3–8)
6 Comprehensive COPD patient education 2 (1–3) 6.5 (4–9)
7 Cost effectiveness of care coordination 3 (2–4) 6.5 (5–10)
8 Case management 3 (2–5) 7 (5–8)
9 Developing a tool for risk satisfaction of patient COPD 3 (3–4) 7 (3–9)
10 Patient-centered medical home 3 (2–4) 7.5 (4–10)
11 Scheduled multidisciplinary team consultation 3 (2–3) 9 (8–10)
Definition of abbreviations: CER ¼ comparative effectiveness research; COPD ¼ chronic obstructive pulmonary disease; IQR ¼ interquartile range.
There were 33 participating stakeholder organizations in the workshop; individual participants are listed in Table 1. Preferences in the Preworkshop Voting were
expressed as importance scores, whereas importance ranks were used for the Final Workshop voting. Ranks were used in an attempt to more easily separate topics by
level of importance. To more clearly observe differences in priorities within each CER area, stakeholders were informed that no two topics should be assigned the same
importance rank. Wide IQRs suggest variation in stakeholder preferences.
TABLE 4. RESULTS OF YEAR 2 WORKSHOP: ACUTE CHRONIC OBSTRUCTIVE PULMONARY DISEASE CARE
Preworkshop Voting Final Workshop Voting
Importance Ranks Normalized and Idealized Priorities
1 (Most Important) to 8 (Most Unimportant) Priority Scores Using AHP
Topic Acute COPD Care Median Rank (IQR) Median Normalized Priority Normalized Priority IQR Idealized Priority
1 Implementation of COPD exacerbation checklist 4 (2–6) 0.22 (0.12–0.26) 1.00 (reference)
2 Comorbid conditions in the acute setting 3 (2–5) 0.20 (0.06–0.36) 0.95
3 Effectiveness and implementation of NIV in
acute respiratory failure
4 (2–5) 0.17 (0.07–0.25) 0.80
4 Role of antibiotics in acute exacerbations 4 (3–6) 0.14 (0.06–0.14) 0.63
5 Quality of care assessment 4 (2–6) 0.12 (0.04–0.19) 0.57
6 Dyspnea in COPD 5 (3–6) 0.07 (0.03–0.08) 0.31
7 Oxygen therapy post exacerbation 7 (4–8) 0.04 (0.02–0.04) 0.19
8 Interventions for acute airway obstruction 6 (4–7) 0.04 (0.02–0.04) 0.18
Definition of abbreviations: AHP ¼ analytic hierarchy process; COPD ¼ chronic obstructive pulmonary disease; IQR ¼ interquartile range; NIV ¼ noninvasive ventilation.
There were 42 participating stakeholder organizations in the workshop; individual participants are listed in Table 1. Wide IQRs suggest variation in stakeholder
preferences. Preferences in the preworkshop voting were expressed as importance ranks, whereas AHP was used to develop normalized and idealized priorities in the
final voting. AHP was used in an attempt to quantify the level of separation in importance across ranked topics. The normalized priorities represent the proportion of the
total importance across all topics that voters ascribe to a particular research topic. The ratio of normalized priorities for any two topics indicates their relative importance
(idealized priority). Thus, the AHP approach ranks topics from most important to least important, but the process also offers the advantage of quantifying the separation
between any two options (e.g., how much more important is the most highly ranked topic compared to any other topic).
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Stakeholders indicated that the Impact on patient-centered health
outcomes was the most important criterion, although a number of
other criteria were also used when selecting among different
COPD CER topics. Importantly, the relative importance of
these criteria in setting research priorities varied across stake-
holder groups. Collectively, these observations suggest that op-
portunities to reach uniform consensus for a single research
priority in CER are limited; it is, however, feasible to differen-
tiate the higher (vs. lower) priority topics and to build a pipeline
of stakeholder-supported CER. Our observations also suggest
that stakeholder support for CER topics may vary depending on
which groups are invited to participate in setting priorities. This
issue highlights the importance of engaging a diverse group of
stakeholders to ensure broad input, which may need to be
enriched further depending on the purpose (e.g., greater in-
volvement of patients for applications in response to funding
opportunities in response to the Patient Centered Outcomes
Research Institute). The workshops included only one represen-
tative of industry, despite our efforts to attract greater involve-
ment by contacting PhRMA, the leading trade organization for
the pharmaceutical industry and biotechnology companies. Also,
other industry representatives (e.g., device manufacturers) were
not participants, and future efforts may benefit from including
a wider cross-section of industry representatives. The optimal
size and breadth of stakeholder organizations for research pri-
oritization activities needs further study (19).
We also found that asking stakeholders to rank rather than
simply rate the importance of topics to be more informative.
We were able to better quantify the relative preferences for dif-
ferent CER topics using the AHP methodology in Year 2 to cal-
culate “idealized priorities.” The AHP methodology also provided
the opportunity to detect inconsistent voting patterns; results were
fortunately reassuring. Of note, we used a limited version of the
AHP in Year 2 and only asked stakeholders to compare the
overall importance of topics. A fully deployed AHP would re-
quire: (1) defining and prioritizing the universe of criteria used
by stakeholders, (2) using AHP to determine how well each
topic satisfies each criterion, and (3) pooling the votes to develop
a prioritized list of research topics. For each criterion, there
would be n(n2 1)/2 pairwise comparisons, where n is the number
of research topics being compared. For the full deployment of the
AHP in Year 2, there would then be 196 pairwise comparisons of
acute care topics (28 pairwise comparisons of topics per criterion3
7 criteria) and another 147 pairwise comparisons of transitions
in care topics, or a total 343 pairwise comparisons. Such an
effort was believed to be impractical for a single meeting and sug-
gests the need for defining and selecting a more parsimonious list of
criteria and CER topics. Furthermore, only about half the stake-
holders provided information about criteria used by their organiza-
tion for setting research priorities. Findings in this report may help
inform future efforts to more fully deploy AHP and thereby more
explicitly link the criteria proposed by stakeholders to the selection
TABLE 5. RESULTS OF YEAR 2 WORKSHOP: TRANSITIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE CARE
Preworkshop Voting Final Workshop Voting
Importance Ranks Normalized and Idealized Priorities
1 (Most Important) to 9 (Most Unimportant) Priority Scores Using AHP
Topic Transitions in COPD Care Median Rank (IQR) Median Normalized Priority Normalized Priority IQR Idealized Priority
1 Integrated healthcare strategies during
transitions in COPD care
2 (1–3) 0.40 (0.23–0.52) 1.00 (reference)
2 Multimorbidity and transitions in
COPD care
3 (2–4) 0.16 (0.07–0.24) 0.40
3 Patient and family activation during
transitions in COPD care
4 (3–5) 0.15 (0.06–0.20) 0.38
4 End of life/palliative care and transitions
in COPD care
4 (2–6) 0.12 (0.05–0.20) 0.31
5 Early diagnosis and treatment of COPD 5 (2–6) N/A* N/A* N/A*
6 Psychosocial barriers during transitions in
COPD care
5 (4–6) 0.09 (0.04–0.12) 0.22
7 Modeling effects of interventions and
transitions in COPD status
6 (4–7) 0.08 (0.03–0.11) 0.22
Definition of abbreviations: AHP ¼ analytic hierarchy process; COPD ¼ chronic obstructive pulmonary disease; IQR ¼ interquartile range; N/A ¼ not applicable.
There were 42 participating stakeholder organizations in the workshop; individual participants are listed in Table 1. Wide IQRs suggest variation in stakeholder
preferences. Preferences in the preworkshop voting were expressed as importance ranks, whereas AHP was used to develop normalized and idealized priorities in the
final voting. AHP was used in an attempt to quantify the level of separation in importance across ranked topics. The normalized priorities represent the proportion of the
total importance across all topics that voters ascribe to a particular research topic. The ratio of normalized priorities for any two topics indicates their relative importance
(idealized priority). Thus, the AHP approach ranks topics from most important to least important, but the process also offers the advantage of quantifying the separation
between any two options (e.g., how much more important is the most highly ranked topic compared to any other topic).
* Topic 5 (Early diagnosis and treatment of COPD) for Transitions in COPD care was not voted on at the workshop because it was folded into Topic 3 (Patient and
family activation during transitions in COPD care) after discussion at the in-person meeting.
TABLE 6. SATISFACTION SURVEY COMPLETED BY STAKEHOLDERS
1 (Strongly Disagree) to
5 (Strongly Agree)
1. The workshop met my expectations. 4 (4–5)
2. I feel that the products of the workshop
will have impact.
4 (4–5)
3. The format and content of the first day
was very useful.
4 (4–5)
4. I would recommend less lecture time
for Day 1.
3 (2–4)
5. I would recommend more discussion time
for Day 1.
4 (3–4)
6. The format and content of the second day
was very useful.
4 (3–4)
7. I believe that the workshop objectives could
be met in a 1-day instead of a 2-day workshop.
2 (2–2.3)
8. I would recommend others to participate in
this event.
4 (3–4)
9. If given the opportunity, I would participate in
this event again.
5 (4–5)
10. Overall, I was very satisfied with this workshop. 4 (4–5)
Definition of abbreviations: CONCERT ¼ COPD Outcomes-based Network for
Clinical Effectiveness and Research Translation; IQR ¼ interquartile range.
Data are presented as median (IQR). Stakeholders were asked to complete an
anonymous satisfaction survey at the end of the Year 1 workshop to help CONCERT
plan for the workshop in Year 2. Thirty-three stakeholder organizations completed
the satisfaction survey.
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of CER priorities. It has been 2 years since the last workshop, and
priorities in COPD CER may have shifted since then. However,
input in CONCERT workshops was broad, and further input can
occur through subsequent efforts to update priorities.
SUMMARY AND CONCLUSIONS OF WORKSHOPS
We used a standard approach to consensus development, the mod-
ified Delphi approach, as well as a novel application of AHP for de-
veloping a national CER agenda for COPD in collaboration with
a diverse set of stakeholders. Studies to improve healthcare delivery,
rather than head-to-head comparisons of medications, were rated as
highest priority. As there was substantial variation in preferences
among stakeholders for specific research topics, researchers may
need to collaborate with different groups of stakeholders depending
onwhich research topics are proposed for study. The various “lessons
learned” from the workshops may help to inform similar efforts to
identify and prioritize CER topics for other health conditions.
A complete list of stakeholder-supported CER priorities is
available in Tables 2 through 5. The rationale and draft research
questions linked to the CER topics is available in Tables E1 to
E3. Stakeholder preferences were strongest for the following
CER topics:
d Chronic care: Spirometry for diagnosis and treatment, Ef-
fectiveness of pulmonary rehabilitation, Effectiveness of
COPD care and guideline translation, and Home care.
d Care coordination: Management of COPD in the presence
of comorbidity, and Pulmonary rehabilitation as a model
for care coordination.
d Acute care: Implementation of COPD exacerbation check-
list, Comorbid conditions in the acute setting, and Effective-
ness and implementation of NIV in acute respiratory failure.
d Transitions in care: Integrated healthcare strategies, Mul-
timorbidity, and Patient and family activation.
Author disclosures are available with the text of this article at www.atsjournals.org.
Acknowledgment: The authors thank the members of the Workshop Organizing
Committee (Gerene Bauldoff, Ph.D., R.N., Ohio State University; Kenneth W. Lin,
M.D., Agency for Healthcare Research and Quality; Barbara Yawn, M.D., M.Sc.,
Olmsted Medical Center; and CONCERT investigators) and the External Advisory
Committee (A. Sonia Buist, M.D., Oregon Health and Sciences University; Stephan
Fihn, M.D., M.P.H., Department of Veterans Affairs; Eddy Lang, M.D., University
of Calgary; David Mannino, M.D., University of Kentucky School of Medicine;
Cynthia S. Rand, Ph.D., Johns Hopkins University; Peter Wyer, M.D., Columbia
University) for their help to plan and conduct the workshops and in reviewing ear-
lier drafts of this report. CONCERT also thanks representatives of stakeholder
organizations that contributed to the workshops. The authors thank Stephanie
Lewis, B.A., Jeffery Charbeneau, M.S., and William T. Summerfelt, Ph.D., for their
help in organizing and conducting the meetings, and Jill Pope and Helene Gussin,
Ph.D., for their help in editing and finalizing this report.
References
1. Institute of Medicine. Initial National Priorities for Comparative Effective-
ness Research. Washington DC: National Academies Press; June, 2009.
2. Pearson SD, Bach PB. How Medicare could use comparative effective-
ness research in deciding on new coverage and reimbursement.Health
Aff (Millwood) 2010;10:1796–1804.
3. U.S. Department of Health and Human Services. Report to the presi-
dent and the congress on comparative effectiveness research. June 30,
2009 [accessed 2012 Jan 8]. Available from: http://www.hhs.gov/recovery/
programs/cer/execsummary.html
4. One hundred eleventh Congress of the United States of America. The
Patient Protection and Affordable Care Act. H.R. 3590. 2010 [accessed
2012 Jan 2]. Available from: http://burgess.house.gov/UploadedFiles/
hr3590_health_care_law_2010.pdf
5. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the
intersection of science and healthcare. Sci Transl Med 2010;2:37cm18.
6. Lieu TA, Au D, Krishnan JA, Moss M, Selker H, Harabin A, Taggart V,
Connors A. Comparative effectiveness research in lung disease and
sleep disorders: recommendations from the National Heart, Lung, and
Blood Institute workshop.Am J Respir Crit Care Med 2011;184:848–856.
7. Mannino DM, Buist AS. Global burden of COPD: risk factors, preva-
lence, and future trends. Lancet 2007;370:765–773.
8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy
for the Diagnosis, Management and Prevention of COPD (2008 edi-
tion) [accessed 2011 Dec 21]. Available from: http://www.goldcopd.org/
9. Akinbamani LJ, Liu X. Chronic Obstructive Pulmonary Disease among
adults aged 18 and over in the United States, 1998–2009. NCHS data
brief, no 63. Hyattsville, MD: National Center for Health Statistics.
2011 [accessed 2012 Jan 2]. Available from: http://www.cdc.gov/nchs/
data/databriefs/db63.htm
10. U.S. Department of Health and Human Services, National Institutes of
Health, National Heart, Lung, and Blood Institute. Morbidity and mor-
tality: 2012 chartbook on cardiovascular, lung and blood diseases [accessed
2013 January 10]. Available from: http://www.nhlbi.nih.gov/resources/docs/
2009_ChartBook.pdf
11. Mularski RA, McBurnie MA, Lindenauer PK, Lee TA, Vollmer WM,
Au DH, Carson SS, Krishnan JA; CONCERT investigator consor-
tium. Comparative effectiveness research in chronic obstructive pul-
monary disease. J Comp Effect Res 2012;1:71–82.
12. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF,
Askham J, Marteau T. Consensus development methods, and their use in
clinical guideline development. Health Technol Assess 1998;2:i–iv, 1–88.
13. American College of Chest Physicians. ACCP Consensus Statement
Development Guide [accessed 2011 Dec 21]. Available from: http://
www.accpstorage.org/newOrganization/guidelines/ConsensusGuide.pdf
14. Vaidya OS, Kumar S. Analytic hierarchy process: an overview of appli-
cations. Eur J Oper Res 2006;169:1–29.
15. Saaty TL. The analytic hierarchy process. Revised edition. Pittsburgh,
PA: RWS Publications; 2000.
16. Saaty TL. A scaling method for priorities in hierarchical structures. J
Math Psychol 1977;15:234–281.
17. Agency for Healthcare Research and Quality. AHRQ Community Forum
[accessed 2012 Sep 3]. Available from: http://effectivehealthcare.ahrq.
gov/index.cfm/who-is-involved-in-the-effective-health-care-program1/ahrq-
community-forum/
18. Pickard AS, Lee TA, Solem CT, Joo MJ, Schumock GT, Krishnan JA. Pri-
oritizing comparative effectiveness research topics via stakeholder involve-
ment: an application in COPD. Clin Pharmacol Ther 2011;90:888–892.
19. Dubois RW, Graff JS. Setting priorities for comparative effectiveness
research: from assessing public health benefits to being open with the
public. Health Aff 2011;30:2235–2242.
TABLE 7. CRITERIA USED BY STAKEHOLDERS TO SELECT
COMPARATIVE EFFECTIVENESS RESEARCH TOPICS
Criterion
1 (Most Important) to 7 (Most
Unimportant) Importance Rank
1. Impact on patient-centered health
outcomes in efficacy studies (magnitude
of benefit demonstrated in efficacy
studies and likelihood to guide daily
practice)
1 (1–2.5)
2. Quality of the evidence about patient-
centered outcomes in efficacy studies
3 (2–4.5)
3. Societal costs of care 4 (3–5)
4. Variability in care, including health
disparities in care
4 (3–5.5)
5. Potential for a difference between efficacy
and effectiveness
5 (2.5–6)
6. Feasibility of effectiveness studies and
implementation studies
5 (4–6)
7. Informs healthcare across diverse areas 5 (4–7)
Data are presented as median rank (interquartile range). Twenty-three stakeholder
organizations completed a survey on criteria used to select comparative effectiveness
research topics after the final prioritization vote at the Year 2 workshop.
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